The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER+ BC?
Lina Pugliano
No relevant relationships to disclose
Dimitrios Zardavas
No relevant relationships to disclose
Marianne Paesmans
No relevant relationships to disclose
Ivana Sestak
No relevant relationships to disclose
Richard D. Gelber
No relevant relationships to disclose
Jack M. Cuzick
No relevant relationships to disclose
Mitchell Dowsett
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - AstraZeneca
Research Funding - AstraZeneca; Pfizer
Ahmad Awada
No relevant relationships to disclose
Martine J. Piccart-Gebhart
Honoraria - AstraZeneca; Novartis
Research Funding - Novartis
Evandro De Azambuja
No relevant relationships to disclose